SRPT Sarepta Therapeutics, Inc.

34.65
-0.37  -1%
Previous Close 35.02
Open 35.14
Price To book 4.48
Market Cap 1.90B
Shares 54,955,000
Volume 1,037,675
Short Ratio 6.37
Av. Daily Volume 1,857,880

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved September 19, 2016.
Eteplirsen
Duchenne muscular dystrophy

Latest News

  1. Scott+Scott, Attorneys at Law, LLP Reminds Investors of its Investigation of Sarepta Therapeutics, Inc.
  2. Biotech Industry Showing Signs of a Revival in 2017: Today's Research on Gilead Sciences and Sarepta Therapeutics
  3. Sarepta Therapeutics and Genethon Announce a Gene Therapy Research Collaboration for the Treatment of Duchenne Muscular Dystrophy
  4. 3 Most Wildly Overvalued Stocks in Biotech (At Least on Paper)
  5. Sarepta Therapeutics, Inc. – Value Analysis (NASDAQ:SRPT) : June 15, 2017
  6. 3 Healthcare Stocks for Ambitious Investors
  7. ETFs with exposure to Sarepta Therapeutics, Inc. : June 15, 2017
  8. Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : SRPT-US : June 14, 2017
  9. Sarepta: Cheap For an Acquirer?
  10. Why Sarepta Therapeutics Stock Imploded in May
  11. Cramer's lightning round: You're playing with fire with this heavily shorted stock
  12. Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  13. Sarepta Therapeutics to Present Company Overview at the Goldman Sachs 38th Annual Global Healthcare Conference
  14. Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US : May 26, 2017
  15. Reporter sues FDA for documents related to Sarepta drug approval
  16. Sarepta's Most Famous Drugs and Medications
  17. Why Zoe's Kitchen, GOL, and Sarepta Therapeutics Slumped Today
  18. Top hedge fund managers shared these 5 trade ideas at the SALT Conference
  19. SALT Spotlight: Why Sarepta is a Buy
  20. Big Fund Managers Offer Up Stock Pick Ideas